Wedbush Reiterates Neutral Rating on Replimune Group, Inc. (REPL)

Market Context

Replimune Group, Inc. operates in the Healthcare sector. The stock currently trades at $11.07 with a market capitalization of $774.6M. The stock has gained 14.7% over the past 52 weeks.

Analyst coverage from Wedbush provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Replimune Group, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Replimune Group, Inc.

Among the 10 most recent ratings: 2 Buy, 6 Hold, 2 Sell.

Date	Firm	Rating	Price Target
Jun 30, 2026	Wedbush	Neutral	N/A
Jun 01, 2026	Wedbush	Neutral	N/A
Apr 13, 2026	Leerink Partners	Market Perform	N/A
Apr 13, 2026	Cantor Fitzgerald	Neutral	N/A
Apr 13, 2026	JP Morgan	Underweight	N/A

Related Tools: Analyst Ratings Dashboard | View REPL Stock Page